Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Javier, Ros"'
Autor:
Romero-López, Cristina ⁎, de San Pedro, Javier Ros, Arteaga-Romero, Francisco, Cuartero-Pérez, Beatriz, Martín-Schrader, Ignacio
Publikováno v:
In Neurocirugía (English Edition) October 2024
Autor:
Marta Rodriguez Castells, Iosune Baraibar, Javier Ros, Nadia Saoudi, Francesc Salvà, Ariadna García, Adriana Alcaraz, Josep Tabernero, Elena Élez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The journey of metastatic colorectal cancer patients is complex and challenging, requiring coordination and collaboration between multiple healthcare providers. Understanding patients’ needs, fears, feelings, concerns, and behaviors is essential fo
Externí odkaz:
https://doaj.org/article/503499159a79490a9f88f3429fb69d9f
Autor:
Iosune Baraibar, Ariadna García, Francesc Salvà, Javier Ros, Nadia Saoudi, Raquel Comas, Gloria Castillo, Mireia Sanchis, Alejandro García-Álvarez, Jorge Hernando, Jaume Capdevila, Marta R Castells, Marc Martí, Stefania Landolfi, Eloy Espín, Begoña Navalpotro, Jorge Guevara, Cristina Dopazo, Paolo Nuciforo, Ana Vivancos, Josep Tabernero, Elena Élez
Publikováno v:
Translational Oncology, Vol 32, Iss , Pp 101668- (2023)
The COVID19 pandemic has affected the spectrum of cancer care worldwide. Early onset colorectal cancer (EOCRC) is defined as diagnosis below the age of 50. Patients with EOCRC faced multiple challenges during the COVID19 pandemic and in some institut
Externí odkaz:
https://doaj.org/article/9f1d98aa7453470c9450c823c97015b9
Autor:
Javier Ros, Francesca Balconi, Iosune Baraibar, Nadia Saoudi Gonzalez, Francesc Salva, Josep Tabernero, Elena Elez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Immune checkpoint inhibitors have reshaped the prognostic of several tumor types, including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95% of metastatic colorectal tumors are microsatellite stable (MSS) in which i
Externí odkaz:
https://doaj.org/article/e0dd495815ce42e69588b352d2a0e7f9
Autor:
Chiara Cremolini, Francesca Corti, Elisabetta Fenocchio, Michael J Overman, Lisa Salvatore, Rossana Intini, Priya Jayachandran, Javier Ros, Maria Elena Elez, Aakash Tushar Shah, Rosalba Miceli, Monica Niger, Giacomo Mazzoli, Francesco Barretta
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Immune checkpoint inhibitors (ICIs) show a tremendous activity in microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), but a consistent fraction of patients does not respond. Prognostic/predictive markers are needed
Externí odkaz:
https://doaj.org/article/7d567d1042404b5e91439f87cbff2736
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
B-type RAF ( BRAF ) -V600E mutations in metastatic colorectal cancer (mCRC) have been described in up to 12% of the patients. This mutation confers a bad prognostic and poor response with standard chemotherapy. Unlike the scenario for BRAF mutant mel
Externí odkaz:
https://doaj.org/article/515265fde44f4a438efdeaae9ab78b22
Publikováno v:
IEEE Access, Vol 9, Pp 60010-60025 (2021)
The aim of this work is to develop a model-based methodology for monitoring lateral track irregularities based on the use of inertial sensors mounted on an in-service train. To this end, a gyroscope is used to measure the wheelset yaw angular velocit
Externí odkaz:
https://doaj.org/article/361479a762b84c89baf8a4931953b093
Autor:
Chiara Cremolini, Giovanni Fucà, Sara Lonardi, Federica Morano, Francesca Corti, Giuseppe Curigliano, Michael Overman, Elisabetta Fenocchio, Massimiliano Salati, Margherita Ambrosini, Lisa Salvatore, Rossana Intini, Priya Jayachandran, Javier Ros, Gabriele Infante, Maria Elena Elez, Marwan Fakih, Aakash Tushar Shah, Floriana Nappo, Silvia Damian, Rosalba Miceli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/a7b576cb763446df83fea7d4010f14b3
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 144-151 (2019)
Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In this review, we outline the ways that lead to hypermuta
Externí odkaz:
https://doaj.org/article/3c238d37868a440c9fd9590d8370f40d
Autor:
Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characteriz
Externí odkaz:
https://doaj.org/article/1009baa5d178419fb4f5aad0d5c307e2